Amphastar Pharmaceuticals, Inc.
AMPH
$28.81
$0.491.73%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 186.98M | 188.82M | 179.39M | 157.63M | 155.65M |
| Total Other Revenue | -455.00K | 2.40M | 3.01M | 14.21M | 22.46M |
| Total Revenue | 186.52M | 191.21M | 182.39M | 171.84M | 178.11M |
| Cost of Revenue | 99.88M | 89.27M | 87.23M | 81.74M | 81.97M |
| Gross Profit | 86.65M | 101.94M | 95.17M | 90.10M | 96.14M |
| SG&A Expenses | 23.36M | 23.82M | 22.30M | 25.05M | 21.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 141.38M | 134.17M | 127.18M | 123.83M | 124.13M |
| Operating Income | 45.14M | 57.05M | 55.22M | 48.01M | 53.98M |
| Income Before Tax | 43.96M | 47.68M | 50.24M | 47.30M | 40.84M |
| Income Tax Expenses | 6.00M | 7.25M | 12.29M | 4.13M | 4.67M |
| Earnings from Continuing Operations | 37.96M | 40.43M | 37.95M | 43.18M | 36.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.96M | 40.43M | 37.95M | 43.18M | 36.17M |
| EBIT | 45.14M | 57.05M | 55.22M | 48.01M | 53.98M |
| EBITDA | 58.58M | 70.45M | 68.37M | 60.99M | 66.81M |
| EPS Basic | 0.79 | 0.83 | 0.78 | 0.90 | 0.75 |
| Normalized Basic EPS | 0.57 | 0.61 | 0.64 | 0.61 | 0.53 |
| EPS Diluted | 0.74 | 0.78 | 0.73 | 0.81 | 0.69 |
| Normalized Diluted EPS | 0.54 | 0.57 | 0.60 | 0.56 | 0.48 |
| Average Basic Shares Outstanding | 47.98M | 48.62M | 48.91M | 48.21M | 47.96M |
| Average Diluted Shares Outstanding | 51.31M | 51.86M | 52.05M | 53.01M | 53.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
